lnterleukin-6 is a determinant of PAI-1 levels in diabetic subjects with the 4G allele at position -675 of the PAI-1 gene

• References

• 1 Juhan-vague I, Alessi MC, Mavri A. et al. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 2003; 01: 1575-9.
• 2 Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004; 27: 813-23.
• 3 Dong J, Fujii S, Li H. et al. Interleukin-6 and mev-astatin regulate plasminogen activator inhibitor-1 through CCAAT/enhancer-binding protein-delta. Arte-rioscler Thromb Vase Biol 2005; 25: 1078-84.
• 4 Rega G, Kaun C, Weiss TW. et al. Inflammatory cytokines interleukin-6 and oncostatin m induce plasminogen activator inhibitor-1 in human adipose tissue. Circulation 2005; 111: 1938-15.
• 5 Dawson SJ, Wiman B, Hamsten A. et al. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993; 268: 10739-15.
• 6 Plomgaard P, Keller P, Keller C. et al. TNF-a but not IL-6, stimulates plasminogen activator inhibitor 1 (PAI-1) expression inhuman subcutaneous adipose tissue. J Appl Physiol 2005; 98: 2019-23.
• 7 Bastelica D, Mavri A, Verdierl M. et al. Relationships between fibrinolytic and inflammatory parameters inhuman adipose tissue: strong contribution of TNF-a receptors to PAI-1 levels. Thromb Haemost 2002; 88: 481-7.
• 8 Panahloo A, Mohamed-Ali V, Gray RP. et al. Plasminogen activator inhibitor-1 (PAI-1) activity post myocardial infarction: the role of acute phase reactants, insulin-like molecules and promoter (4G/5G) polymorphism in the PAI-1 gene. Atherosclerosis 2005; 168: 297-304.
• 9 Hoekstra T, Geleijnse JM, Schouten EG. et al. Plasminogen activator inhibitor-type I: its plasma determinants and relation with cardiovascular risk. Thromb Haemost 2004; 91: 861-72.